Bacterial Pneumonia Clinical Trial
Official title:
A Phase Ib/IIa, Randomised, Double Blind, Parallel Group, Placebo Controlled, Multicentre Study to Assess the Safety and Efficacy of Expanded Cx611 Allogeneic Adipose-derived Stem Cells (eASCs) for the Intravenous Treatment of Adult Patients With Severe Community-acquired Bacterial Pneumonia and Admitted to the Intensive Care Unit
The purpose of this randomised, multicentre, double-blind, placebo-controlled, phase Ib/IIa study is to assess the safety, tolerability and efficacy of eASCs (Cx611) administered intravenously as adjunctive therapy, therefore in addition to standard of care (SoC) therapy, to patients with severe community-acquired bacterial pneumonia (sCABP). The completion of this study will contribute to the basic knowledge on stem cells and their mode-of-action, and has a large translational character, i.e. to document the safety and explore the efficacy of Cx611 in patients with sCABP.
The purpose of this randomised, multicentre, double-blind, placebo-controlled, phase Ib/IIa study is to assess the safety, tolerability and efficacy of eASCs (Cx611) administered intravenously as adjunctive therapy, therefore in addition to standard of care (SoC) therapy, to patients with severe community-acquired bacterial pneumonia (sCABP). The key objectives of this study are to: Primary objective: Investigate the safety profile of two allogeneic Cx611 80 mL infusions administered through a central line within 3 days (on days 1 and 3) at a dose of 160 million cells each (320 million cells total) and to monitor any adverse event and potential immunological host responses against the administered cells during 90 days of follow-up after the first infusion. Secondary objective: Explore the clinical efficacy of Cx611 in terms of a reduction of the duration of mechanical ventilation and/or need for vasopressors and/or improved survival, and/or clinical cure of the sCABP, and other efficacy-related endpoints. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT01570192 -
Clinical Trials to Reduce the Risk of Antimicrobial Resistance
|
Phase 2 | |
| Recruiting |
NCT04952337 -
Clinical, Molecular and Functional Biomarkers for PROgnosis, Pathomechanisms and Treatment Strategies of COVID-19 (PROVID) - (PROVID-CAPNETZ)
|
||
| Completed |
NCT02493764 -
Imipenem/Relebactam/Cilastatin Versus Piperacillin/Tazobactam for Treatment of Participants With Bacterial Pneumonia (MK-7655A-014)
|
Phase 3 | |
| Completed |
NCT02531438 -
Omadacycline vs Moxifloxacin for the Treatment of CABP (EudraCT #2013-004071-13)
|
Phase 3 | |
| Completed |
NCT00079885 -
Study Evaluating Tigecycline vs Levofloxacin in Hospitalized With Community-Acquired Pneumonia
|
Phase 3 | |
| Recruiting |
NCT05629741 -
A 2-Part First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of CMTX-101
|
Phase 1 | |
| Completed |
NCT05417997 -
Effect of Kunamin in SARS-CoV-2 RT-PCR Positive Covid-19 Patients
|
Phase 3 | |
| Withdrawn |
NCT00645619 -
Use of TREM-1 Protein to Differentiate Viral and Bacterial Pneumonias in Intubated Children
|
||
| Completed |
NCT00509106 -
Comparative Study of Ceftaroline vs. Ceftriaxone in Adults With Community-Acquired Pneumonia
|
Phase 3 | |
| Completed |
NCT00080496 -
Study Evaluating Tigecycline Versus Imipenem/Cilastatin in Hospital-Acquired Pneumonia
|
Phase 3 | |
| Completed |
NCT00621504 -
Comparative Study of Ceftaroline vs. Ceftriaxone in Adult Subjects With Community-Acquired Pneumonia
|
Phase 3 | |
| Completed |
NCT00124020 -
Comparison of Telavancin and Vancomycin for Hospital-acquired Pneumonia Due to Methicillin-resistant Staphylococcus Aureus
|
Phase 3 | |
| Completed |
NCT00081575 -
Study Comparing Tigecycline vs. Levofloxacin in Subjects Hospitalized With Community-Acquired Pneumonia
|
Phase 3 | |
| Completed |
NCT00451386 -
Ertapenem Study in Pediatric Patients Who Have Urinary Tract Infections, Skin Infections or Community-acquired Pneumonia (0826-036)
|
Phase 2 | |
| Recruiting |
NCT03752320 -
Multiplex Polymerase Chain Reaction in Postoperative Pneumonia After Thoracic Surgery
|
||
| Active, not recruiting |
NCT04779242 -
Omadacycline vs. Moxifloxacin for the Treatment of Community-Acquired Bacterial Pneumonia
|
Phase 3 | |
| Completed |
NCT00763620 -
Assessment of the Diagnostic Capacity of the Mini-broncho Alveolar Lavage Performed Through a Suction Catheter
|
N/A | |
| Completed |
NCT00107952 -
Comparison of Telavancin and Vancomycin for Hospital-acquired Pneumonia Due to Methicillin-resistant Staphylococcus Aureus
|
Phase 3 | |
| Terminated |
NCT03862040 -
Cefiderocol Concentrations in the Lungs of Hospitalized Patients With Bacterial Pneumonia
|
Phase 1 | |
| Recruiting |
NCT05531149 -
Efficacy and Safety of Trimodulin (BT588) in Subjects With CAP Including COVID-19 Pneumonia
|
Phase 3 |